Amgen Reveals First Figures For US Humira Rival
Q1 Sales Disclosed For Amjevita Biosimilar As Brand Loses A Quarter Of Value In US
As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.
